Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells 2,698 Shares of Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLSGet Rating) insider Victoria L. Brown sold 2,698 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Friday, June 17th. The shares were sold at an average price of $45.00, for a total value of $121,410.00. Following the completion of the sale, the insider now directly owns 24,974 shares in the company, valued at approximately $1,123,830. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

APLS opened at $43.98 on Thursday. The business has a fifty day simple moving average of $43.83 and a 200 day simple moving average of $44.95. Apellis Pharmaceuticals, Inc. has a 1 year low of $27.50 and a 1 year high of $73.00. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.58 and a current ratio of 8.85.

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) last released its earnings results on Wednesday, May 4th. The company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.07). Apellis Pharmaceuticals had a negative net margin of 866.81% and a negative return on equity of 607.37%. During the same period in the prior year, the company earned ($2.32) EPS. As a group, sell-side analysts anticipate that Apellis Pharmaceuticals, Inc. will post -5.56 EPS for the current year.

Several large investors have recently added to or reduced their stakes in APLS. Jennison Associates LLC lifted its position in shares of Apellis Pharmaceuticals by 45.2% during the 1st quarter. Jennison Associates LLC now owns 2,704,390 shares of the company’s stock valued at $137,410,000 after acquiring an additional 842,233 shares during the period. Perceptive Advisors LLC lifted its position in shares of Apellis Pharmaceuticals by 136.0% during the 4th quarter. Perceptive Advisors LLC now owns 1,451,700 shares of the company’s stock valued at $68,636,000 after acquiring an additional 836,700 shares during the period. Vanguard Group Inc. lifted its position in shares of Apellis Pharmaceuticals by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 8,569,170 shares of the company’s stock valued at $435,400,000 after acquiring an additional 652,071 shares during the period. Pictet Asset Management SA acquired a new position in shares of Apellis Pharmaceuticals during the 4th quarter worth $30,560,000. Finally, Bellevue Group AG raised its holdings in shares of Apellis Pharmaceuticals by 1,255.4% during the 4th quarter. Bellevue Group AG now owns 650,591 shares of the company’s stock worth $30,760,000 after buying an additional 602,591 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Several research analysts have weighed in on APLS shares. JPMorgan Chase & Co. boosted their price target on Apellis Pharmaceuticals from $66.00 to $69.00 and gave the stock an “overweight” rating in a research report on Monday, April 4th. Stifel Nicolaus started coverage on Apellis Pharmaceuticals in a research report on Thursday, June 16th. They set a “buy” rating on the stock. Robert W. Baird boosted their price target on Apellis Pharmaceuticals from $83.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 16th. Roth Capital downgraded Apellis Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $40.00 target price for the company. in a research note on Wednesday, April 13th. Finally, Credit Suisse Group lifted their target price on Apellis Pharmaceuticals to $49.00 in a research note on Friday, May 20th. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $69.64.

About Apellis Pharmaceuticals (Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

Further Reading

Insider Buying and Selling by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.